nos: 547 -609 TCT-547 Efficacy and safety of platinum-chromium everolimus-eluting stents compared with other second-generation drug-eluting stents. Meta-analysis from 5 randomized trials including 7,896 patients BACKGROUND Platinum-chromium alloy has been recently incorporated to the drug-eluting stent platforms, mainly everolimus-eluting stents (Promus Element -PE-stent). The objective of the study was to evaluate the efficacy and safety of PE in comparison with other second-generation drug-eluting stents.
RESULTS Clinical events at 12 months were infrequent (target lesion revascularization < 2%), and numerically lower in patients allocated to PE, but differences were not statistically different (see table) . The rate of definitive/probable stent thrombosis after PE implantation at 1 year was < 0.5%. RESULTS Sirolimus release kinetics from DFS were biexponential ( Fig  A, R2>0.99 ), speaking to the existence of an easily available and releasable pool of drug that elutes within the first day (first time point) following arterial implantation, plus a pool of sustained-eluting drug with a half-life of 28-32 days. Notably, the fraction of drug load that is sustained-eluting and its half-life of release both decreased with increasing hole-size ( Fig B) . Tissue content tracked the first order elution of the sustained-eluting drug pool down to an apparent plateau level of 0.51AE0.03 ng/mg ( Fig C) and was not statistically different for any of the hole sizes evaluated (15, 20, and 25 mm).
PE stent
CONCLUSIONS Though drug in tissue from DFS with hole-sizes of 15 to 25mm were bioequivalent, hole-size emerged as a design parameter for predictably titrating local tissue retention of DFS eluted drug. BACKGROUND The advent of bioresorbable scaffolds is redrawing attention to accurate device size selection. While significant undersizing often results in incomplete strut apposition (ISA) or underexpansion, possible impact of oversized stent implantation on arterial wall injury has not been systematically investigated with drug-eluting stents (DES).
METHODS To evaluate the effect of stent oversizing on acute and long-term outcomes, serial (baseline and 6-12 months) coronary angiography and IVUS were performed in 2931 lesions treated with DES (355 sirolimus, 846 paclitaxel, 1387 zotarolimus, and 343 everolimus). The degree of stent oversizing (%SO) to angiographic reference vessel diameter (RVD) was calculated as (nominal stent diameter -RVD) / RVD x 100 (%). Post-procedural stent expansion was calculated by IVUS as minimum stent area divided by the average reference lumen area. Clinical outcomes including target lesion revascularization (TLR) and stent thrombosis were followed for 1 year.
RESULTS Overall, smaller pre-procedural RVD was linearly associated with higher %SO (r¼-0.670, p<0.001). Significant stent oversizing (defined as %SO>10%) was found in 82% of small RVD (<2.75 mm) group and 33% of larger RVD (!2.75 mm) group. The significant oversizing group underwent less post-dilatation (p¼0.002), but achieved greater stent expansion (p<0.001) and less ISA (p<0.001) without increase of edge dissection after procedure. When stratified by vessel size and stent oversizing (no difference in DES type among the 4 groups, p¼0.525), progressive decreases of angiographic binary restenosis and TLR rates (left figure) were found in favor of larger vessel size and oversized stents. Stent thrombosis was observed the most in the small RVD with low %SO group compared with the other subgroups (p¼0.040) (right figure) .
CONCLUSIONS In this pooled data analysis, no negative impact of stent oversizing was documented with respect to procedural and long-term clinical outcomes. Clinical adverse events appeared to be primarily related to vessel size itself, rather than the selection of a stent larger than the vessel size. In particular, small vessels treated with a smaller stent were associated with greater adverse events, suggesting that aggressive selection of larger stents with appropriate attention to edge effects may optimize long-term outcomes even in DES implantation.
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